| This week's sponsor is SynteractHCR. | | | |
Featured Story | | | Tuesday, August 29, 2017 AstraZeneca has teamed up with Takeda to co-develop its preclinical Parkinson’s disease candidate MEDI1341. The deal sees Takeda committing to pay AstraZeneca up to $400 million (€332 million) for the chance to co-develop the alpha-synuclein antibody. |
|
|
Top Stories Tuesday, August 29, 2017 Jazz is paying $75 million and committing to $100 million in R&D funding to buy into ImmunoGen’s early-stage pipeline. The deal gives Jazz an option to pick up worldwide rights to two hematology antibody-drug conjugates (ADCs) and a third as-yet-unidentified program. Tuesday, August 29, 2017 A couple of months back, Merck posted a surprise win for its troubled CETP candidate anacetrapib when it hit its primary endpoint. Tuesday, August 29, 2017 After just two years, Five Prime Therapeutics has ducked out of an immuno-oncology collaboration with InhibRx that on signing had a value of more than $460 million. Tuesday, August 29, 2017 The ex-chief medical officer of uniQure has left his post and moved over to the small, rare-disease biotech Therachon. Tuesday, August 29, 2017 Fresh off a $500 million initial financing round late May, Outcome Health has already set out to improve and expand its health intelligence offerings with the help of a new scientific collaborator: Harvard Health Publications. Tuesday, August 29, 2017 A team of researchers at the University of California has discovered an existing drug that boosts the production of immune cells known as “memory” CD8+ T cells. The finding could enhance both cancer immunotherapy and vaccine development. Monday, August 28, 2017 Cardiovascular drugs may not be the top field in terms of sales or market growth rate. But heart disease and related ailments remain the biggest cause of death in the U.S. We’ve put together this list as a state-of-the-market snapshot, coinciding with the European Society of Cardiology meeting this week. Resources Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. 2nd Strategic Partnerships for Drug Repurposing October 26-27, 2017 | Boston, MA Now Accepting Applications: Fierce Innovation Awards Life Science Edition FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London 11th Digital Pharma East October 3-6, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA |
